Title :

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Author(s) :

Hernandez-Boluda, Juan Carlos [Auteur]
Pereira, Arturo [Auteur]
Krger, Nicolaus [Auteur]
Beelen, Dietrich W. [Auteur]
Robin, Marie [Auteur]
Bornhauser, Martin [Auteur]
Angelucci, Emanuele [Auteur]
Vitek, Antonin [Auteur]
Blau, Igor Wolfgang [Auteur]
Niittyvuopio, Riitta [Auteur]
Finke, Jurgen [Auteur]
Cornelissen, Jan J. [Auteur]
Passweg, Jakob R. [Auteur]
Dreger, Peter [Auteur]
Petersen, Eefke [Auteur]
Kanz, Lothar [Auteur]
Sanz, Jaime [Auteur]
Zuckerman, Tsila [Auteur]
Zinger, Nienke [Auteur]
Iacobelli, Simona [Auteur]
Hayden, Patrick J. [Auteur]
Czerw, Tomasz [Auteur]
Mclornan, Donal P. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Journal title :

Leukemia

Abbreviated title :

Leukemia

Publication date :

2020-04-14

ISSN :

1476-5551

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This ...
Show more >We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2021-07-06T12:45:37Z